Monoclonal antibody treatment for severe uncontrolled asthma in Spain

Background: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. Objective: To evaluate th...

Descripción completa

Detalles Bibliográficos
Autores: Casas-Maldonado, Francisco, Alvarez Gutiérrez, Francisco Javier|||0000-0002-0175-2824, Blanco-Aparicio, Marina|||0000-0002-5012-1746, Domingo, Christian|||0000-0001-8358-773X, Cisneros, Carolina|||0000-0003-4297-4199, Soto Campos, Gregorio, Román Bernal, Berta, González-Barcala, Francisco-Javier|||0000-0001-5847-4784
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:280643
Acceso en línea:https://ddd.uab.cat/record/280643
https://dx.doi.org/urn:doi:10.1080/02770903.2021.1978483
Access Level:acceso abierto
Palabra clave:Severe asthma
Monoclonal antibodies
Mepolizumab
Dupilumab
Omalizumab
Reslizumab
Benralizumab
id ES_7e2e6f221cbab8db1b3bdfeba3228247
oai_identifier_str oai:ddd.uab.cat:280643
network_acronym_str ES
network_name_str España
repository_id_str
spelling Monoclonal antibody treatment for severe uncontrolled asthma in Spainanalytical mapCasas-Maldonado, FranciscoAlvarez Gutiérrez, Francisco Javier|||0000-0002-0175-2824Blanco-Aparicio, Marina|||0000-0002-5012-1746Domingo, Christian|||0000-0001-8358-773XCisneros, Carolina|||0000-0003-4297-4199Soto Campos, GregorioRomán Bernal, BertaGonzález-Barcala, Francisco-Javier|||0000-0001-5847-4784Severe asthmaMonoclonal antibodiesMepolizumabDupilumabOmalizumabReslizumabBenralizumabBackground: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. Objective: To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. Methods: An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. Results: Data from 90 hospitals were analyzed (Response rate 64.3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. Conclusion: The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.Informa HealthcareUniversitat Autònoma de Barcelona. Departament de Medicina 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501AMhttp://purl.org/coar/version/c_ab4af688f83e57aainfo:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/280643https://dx.doi.org/urn:doi:10.1080/02770903.2021.1978483reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.https://rightsstatements.org/vocab/InC/1.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2806432026-06-06T12:50:31Z
dc.title.none.fl_str_mv Monoclonal antibody treatment for severe uncontrolled asthma in Spain
analytical map
title Monoclonal antibody treatment for severe uncontrolled asthma in Spain
spellingShingle Monoclonal antibody treatment for severe uncontrolled asthma in Spain
Casas-Maldonado, Francisco
Severe asthma
Monoclonal antibodies
Mepolizumab
Dupilumab
Omalizumab
Reslizumab
Benralizumab
title_short Monoclonal antibody treatment for severe uncontrolled asthma in Spain
title_full Monoclonal antibody treatment for severe uncontrolled asthma in Spain
title_fullStr Monoclonal antibody treatment for severe uncontrolled asthma in Spain
title_full_unstemmed Monoclonal antibody treatment for severe uncontrolled asthma in Spain
title_sort Monoclonal antibody treatment for severe uncontrolled asthma in Spain
dc.creator.none.fl_str_mv Casas-Maldonado, Francisco
Alvarez Gutiérrez, Francisco Javier|||0000-0002-0175-2824
Blanco-Aparicio, Marina|||0000-0002-5012-1746
Domingo, Christian|||0000-0001-8358-773X
Cisneros, Carolina|||0000-0003-4297-4199
Soto Campos, Gregorio
Román Bernal, Berta
González-Barcala, Francisco-Javier|||0000-0001-5847-4784
author Casas-Maldonado, Francisco
author_facet Casas-Maldonado, Francisco
Alvarez Gutiérrez, Francisco Javier|||0000-0002-0175-2824
Blanco-Aparicio, Marina|||0000-0002-5012-1746
Domingo, Christian|||0000-0001-8358-773X
Cisneros, Carolina|||0000-0003-4297-4199
Soto Campos, Gregorio
Román Bernal, Berta
González-Barcala, Francisco-Javier|||0000-0001-5847-4784
author_role author
author2 Alvarez Gutiérrez, Francisco Javier|||0000-0002-0175-2824
Blanco-Aparicio, Marina|||0000-0002-5012-1746
Domingo, Christian|||0000-0001-8358-773X
Cisneros, Carolina|||0000-0003-4297-4199
Soto Campos, Gregorio
Román Bernal, Berta
González-Barcala, Francisco-Javier|||0000-0001-5847-4784
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona. Departament de Medicina
dc.subject.none.fl_str_mv Severe asthma
Monoclonal antibodies
Mepolizumab
Dupilumab
Omalizumab
Reslizumab
Benralizumab
topic Severe asthma
Monoclonal antibodies
Mepolizumab
Dupilumab
Omalizumab
Reslizumab
Benralizumab
description Background: Monoclonal antibodies (mABs) have become available to treat more efficiently patients with severe uncontrolled asthma (SUA). However, the use of mABs is lower than expected given the prevalence of SUA, with significant disparities in the use of these treatments. Objective: To evaluate the proportion of patients with SUA treated with mABs in Spain, and to analyze some of the factors that could determine these prescription patterns. Methods: An analysis was performed on the data provided from the Hospitals National Health System (NHS) 2018 catalogue where Chest Diseases Department and a Hospital Pharmacy were available. Random sampling was performed to determine the sample size, stratifying proportionally by geographic area and hospital level. Characteristics of the participating sites, as well as the prescribing of mABs were collected, which included geographic area, hospital levels, prescribing medical specialities, types of clinics, and mABs prescribed. Results: Data from 90 hospitals were analyzed (Response rate 64.3%). Level 4 hospitals, the Canary Islands geographical area, and the presence of a high complexity Asthma Healthcare Unit (ACU) were associated with a higher probability that the SUA was treated with mABs. Conclusion: The map of the prescribing of mABs for SUA in Spain shows a significant variation by geographic area, hospital level, type of clinic, and the accreditation level of the ACUs. At the current time, there appears to be significant under-prescribing of these treatments.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
AM
http://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/280643
https://dx.doi.org/urn:doi:10.1080/02770903.2021.1978483
url https://ddd.uab.cat/record/280643
https://dx.doi.org/urn:doi:10.1080/02770903.2021.1978483
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://rightsstatements.org/vocab/InC/1.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://rightsstatements.org/vocab/InC/1.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411717731057664
score 15,300724

Similares en LA Referencia